A case with cyclosporine-associated thrombotic microangiopathy in early stage after kidney transplantation salvage with tacrolimus and plasma exchange
Böbrek transplantasyonu sonrası erken dönemde siklosporin ilişkili trombotik mikroanjiyopati gelişen olgunun takrolimus ve plazma değişimi ile tedavisi
We review a successfully treated case in which cyclosporine associated TMA developed after a second kidney transplantation in this article.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Thrombotic microangiopathy (TMA)/uremic hemolytic syndrome is a rarely seen complication after kidney transplantation and might be associated with cyclosporine-A.
📊
Key Findings & Data:It can be confused with acute rejection when no systemic symptoms are present.
💡
Conclusion & Impact:We review a successfully treated case in which cyclosporine associated TMA developed after a second kidney transplantation in this article.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Thrombotic microangiopathy (TMA)/uremic hemolytic syndrome is a rarely seen complication after kidney transplantation and might be associated with cyclosporine-A. It can be confused with acute rejection when no systemic symptoms are present. We review a successfully treated case in which cyclosporine associated TMA developed after a second kidney transplantation in this article.
Özet
Trombotik mikroanjiopati (TMA)/hemolitik üremik sendrom böbrek transplantasyonu sonrası nadir görülen bir komplikasyon olup siklosporin-A ile ilişkili olabilir. Sistemik bulgular olmadığında akut rejeksiyon ile karışabilir. Yazımızda ikinci kez böbrek transplantasyonu yapıldıktan sonra siklosporin ilişkili TMA gelişen ve başarılı şekilde tedavi edilen bir olgu sunulacaktır.
🔖
Cite This Article
YILDIRIM, T., ARICI, M., ERDEM, Y., TURGAN, Ç., AKİ, F. T., AYBAL, A., YASAVUL, Ü. (2022). A case with cyclosporine-associated thrombotic microangiopathy in early stage after kidney transplantation salvage with tacrolimus and plasma exchange. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi, Cilt: 19 - Sayı: 1, 62–64. https://ajindex.com/articles/636484
Zarifian A, Meleg-Smith S, O’donovan R, Tesi RJ, Batuman V: Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int 1999;55:2457-2466 2. Reynolds JC, Agodoa LY, Yuan CM, Abbott KC: Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis 2003;42:1058-1068 3. Pham PT, Danovitch GM, Wilkinson AH, Gritsch HA, Pham PC, Eric TM, Kendrick E, Charles LR, Tsai HM: Inhibitors of ADAMTS13: a potential factor in the cause of thrombotic microangiopathy in a renal allograft recipient. Transplantation 2002;74:1077-1080 4. Zoja C, Furci L, Ghilardi F, Zilio P, Benigni A, Remuzzi G: Cyclosporin-induced endothelial cell injury. Lab Invest 1986;55:455-462 5. Remuzzi G, Bertani T: Renal vascular and thrombotic effects of cyclosporine. Am J Kidney Dis 1989;13:261-272 6. Schwimmer J, Nadasdy TA, Spitalnik PF, Kaplan KL, Zand MS: De novo thrombotic microangiopathy in renal transplant recipients: A comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am J Kidney Dis 2003;41:471-479 7. Franz M, Regele H, Schmaldienst S, Stummvoll HK, Hörl WH, Pohanka E: Posttransplant hemolytic uremic syndrome in adult retransplanted kidney graft recipients: advantage of FK506 therapy? Transplantation 1998; 15;66(9):1258-1262 8. Mor E, Lustig S, Tovar A, Bar-Nathan N, Shharabani E, Shapira Z, Yusim A: Thrombotic microangiopathy early after kidney transplantation: Hemolytic uremic syndrome or vascular rejection? Transplant Proc 2000; 32(4):686-687 9. Ponticelli C, Banfi G: Thrombotic microangiopathy after kidney transplantation. Transpl Int 2006;19:789-794